Cargando…
Neuroimaging Biomarkers for Alzheimer’s Disease
Currently, over five million Americans suffer with Alzheimer’s disease (AD). In the absence of a cure, this number could increase to 13.8 million by 2050. A critical goal of biomedical research is to establish indicators of AD during the preclinical stage (i.e. biomarkers) allowing for early diagnos...
Autores principales: | Márquez, Freddie, Yassa, Michael A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555939/ https://www.ncbi.nlm.nih.gov/pubmed/31174557 http://dx.doi.org/10.1186/s13024-019-0325-5 |
Ejemplares similares
-
Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer's disease
por: Holbrook, Andrew J., et al.
Publicado: (2020) -
Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease
por: Brickman, Adam M., et al.
Publicado: (2022) -
Transfer Learning for Alzheimer’s Disease through Neuroimaging Biomarkers: A Systematic Review
por: Agarwal, Deevyankar, et al.
Publicado: (2021) -
Editorial: Neuroimaging Biomarkers and Cognition in Alzheimer's Disease Spectrum
por: Chen, Jiu, et al.
Publicado: (2022) -
Neuroimaging of Mouse Models of Alzheimer’s Disease
por: Jullienne, Amandine, et al.
Publicado: (2022)